4 recruiting, 1 terminated. 5 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 5 | Recruiting 4, Terminated 1 |
Follow Autonomic Dysfunction: new trials by email Literature Review of Autonomic Dysfunction trials Research Report on Autonomic Dysfunction
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Autonomic and Renal Contributions to Hypertension With ADT Gonadotropin Releasing Hormone Agonists (GNRH), Androgen receptor (AR) inhibitor, Placebo - Androgen Deprivation Therapy, Prostate Cancer | Phase 4 | Recruiting | Virginia Commonwealth University | 50 | 2026-08-01 | 2026-09-30 |
| Cervicothoracic Sympathetic Block Evaluation for Post COVID Condition 5 mL of 0.25% bupivacaine with epinephrine (1:200,000), Placebo (Saline) Control - Autonomic Dysfunction | Phase 4 | Recruiting | University Health Network, Toronto | 78 | 2026-05-19 | 2026-10-09 |
| LANdiolol to Avoid TAchycardia in Patients at Risk for Cardiovascular Events Undergoing Major Non-cardiac Surgery Landiolol - Perioperative Myocardial Injury, Autonomic Dysfunction | Phase 4 | Recruiting | Insel Gruppe AG, University Hospital Bern | 114 | 2026-04-24 | 2026-05-05 |
| Efficacy and Safety of Vespireit, Prolonged-release Tablets, in Patients With Autonomic Dysfunction Syndrome Accompanied by Functional Vertigo Vespireit, Arlevert - Vertigo, Autonomic Dysfunction | Phase 4 | Recruiting | Valenta Pharm JSC | 160 | 2024-01-24 | 2025-06-15 |
| Contributions to Hypertension With Androgen Deprivation Therapy Gonadotropin Releasing Hormone Agonists (GNRH), Androgen receptor (AR) inhibitor, Placebo - Androgen Deprivation Therapy, Prostate Cancer | Phase 4 | Terminated | University of Colorado, Denver | 10 | 2023-09-20 | 2026-09-02 |
Primary Dysautonomias (5) · Hypertension (2) · Kidney Diseases (2) · Prostatic Neoplasms (2) · Vertigo (1)
Autonomic Nervous System Diseases (5) · Nervous System Diseases (5) · Cardiovascular Diseases (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Genital Diseases (2) · Genital Diseases, Male (2) · Genital Neoplasms, Male (2) · Male Urogenital Diseases (2) · Neoplasms (2) · Neoplasms by Site (2) · Prostatic Diseases (2) · Urogenital Diseases (2) · Urogenital Neoplasms (2) · Urologic Diseases (2)
Flutamide (2) · Leuprolide (2) · Receptors, Androgen (2) · bicalutamide (2) · Bupivacaine (1) · Epinephrine (1) · Goserelin (1) · Saline Solution (1) · Sodium Chloride (1) · cinnarizine, dimenhydrinate drug combination (1) · enzalutamide (1) · landiolol (1)
Insel Gruppe AG, University Hospital Bern (1) · University Health Network, Toronto (1) · University of Colorado, Denver (1) · Valenta Pharm JSC (1) · Virginia Commonwealth University (1)
United States (2) · Canada (1) · Russia (1) · Switzerland (1)
Matthew Babcock, PhD (2) · Anuj Bhatia, MD, PhD (1)
K01HL164978 (1)